TL;DR
This paper introduces a novel triple-component co-processed excipient (lactose, MCC, L-HPC) developed via solvent evaporation. This new excipient significantly improves the tableting performance of orally disintegrating tablets (ODTs), leading to faster disintegration, quicker dissolution, and enhanced drug absorption for metoclopramide compared to conventional tablets.
What Problem Does This Paper Address?
Orally disintegrating tablets (ODTs) offer significant advantages, particularly for patients with swallowing difficulties, as they dissolve rapidly in the mouth without water. However, manufacturing ODTs via direct compression, a preferred method due to its simplicity and cost-effectiveness, requires excipients with excellent flowability and compressibility. Existing single-component excipients often fall short of these requirements, leading to challenges in producing uniform and effective ODTs. This paper addresses the need for advanced, multi-functional co-processed excipients that can overcome these limitations and enable efficient direct compression for ODT production.
Methods
The researchers developed a novel co-processed excipient by combining lactose (filler/sweetener), microcrystalline cellulose (MCC, filler), and low-substituted hydroxypropyl cellulose (L-HPC, disintegrant/binder) using a wet-method solvent evaporation technique.
Key methodological steps included:
- Single-Factor Experiments: To screen the effects of different fillers, disintegrants, and heat treatment parameters on the co-processed excipient's properties.
- Box-Behnken Design: A statistical experimental design was employed to optimize the formulation ratios of water, MCC, and lactose relative to L-HPC.
- Characterization of Co-Processed Excipients: A comprehensive evaluation of the developed excipients' properties, including:
- Flowability: Measured by angle of repose, bulk density, tapped density, Carr's index, and Hausner ratio.
- Compactibility: Assessed through tensile strength measurements of compressed tablets.
- Hygroscopicity: Determined by plotting moisture absorption curves under varying relative humidity.
- Surface Morphology: Examined using Scanning Electron Microscopy (SEM).
- Physical States: Analyzed using Infrared (IR) spectroscopy, X-ray Diffraction (XRD), Thermogravimetric Analysis (TGA), and Differential Scanning Calorimetry (DSC) to understand structural changes and thermal stability.
- Preparation of Metoclopramide ODTs: The optimized co-processed excipient was used to formulate metoclopramide ODTs via direct compression.
- Characterization of MCP ODTs: The prepared ODTs were evaluated for:
- Disintegration Time: Using a custom-designed device simulating oral disintegration.
- In Vitro Dissolution: Measured using the USP rotating basket method.
- In Vivo Pharmacokinetics: A study in beagle dogs compared the plasma concentration-time profiles of the developed MCP ODTs against a conventional metoclopramide tablet (Reglan®).
Datasets
Not discussed in the paper. The study primarily relies on experimental data generated from the synthesis and characterization of the co-processed excipients and the prepared ODTs.
Key Insights and Ideas
- Synergistic Effect of Triple Co-processing: Combining lactose, MCC, and L-HPC in a co-processed form creates a synergistic effect, yielding superior flowability and compressibility compared to individual components or simple physical mixtures.
- Solvent Evaporation as an Effective Technique: This method successfully produced dense, uniform particles with enhanced properties, overcoming the limitations of simple physical blending.
- Transformation of Lactose: The co-processing appears to induce a conversion of α-lactose to β-lactose, which contributes to improved compactibility and altered thermal properties.
- Optimized Ratios are Crucial: The Box-Behnken design successfully identified optimal ratios for water, MCC, and lactose relative to L-HPC, balancing disintegration, flow, and compressibility.
- Enhanced Drug Delivery: The developed ODTs demonstrated significantly faster disintegration and dissolution, leading to a higher and more rapid absorption of metoclopramide in vivo.
Key Results
- Improved Excipient Properties: The co-processed excipients exhibited an angle of repose of 36.52°, a Carr's index of 18.75%, and a Hausner ratio of 1.23, indicating favorable flowability and compressibility suitable for direct compression.
- Rapid ODT Performance: The optimized MCP ODTs achieved disintegration times of less than 25 seconds and complete dissolution within 5 minutes.
- Enhanced Pharmacokinetics: In vivo studies showed that MCP ODTs resulted in a 1.60-fold higher C<sub>max</sub> (maximum plasma concentration) compared to conventional Reglan® tablets, with a shorter T<sub>max</sub> (time to reach C<sub>max</sub>).
- Bioequivalence: While C<sub>max</sub> showed non-equivalence, AUC<sub>0-t</sub> and AUC<sub>INF_obs</sub> indicated bioequivalence between the MCP ODTs and the conventional tablets, suggesting comparable overall drug exposure.
Limitations and Future Work
- Limited Sample Size in Pharmacokinetic Study: The authors acknowledge that the relative error due to a limited sample size in the pharmacokinetic study might affect data accuracy and suggest that future studies should focus on validation.
- Further Validation of ODT Efficiency: While promising, the paper suggests that future studies should be performed to confirm the therapeutic efficiency of the developed MCP ODTs.
- Broader Drug Applicability: The study focused on metoclopramide. Future work could explore the applicability of these co-processed excipients for formulating ODTs of other drugs, particularly those with poor solubility.
- Long-term Stability: While thermal analysis was performed, long-term stability studies of the co-processed excipients and the final ODT formulations under various storage conditions would be beneficial.
Summary updated